Otonomy Reports Fourth Quarter and Full Year 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Otonomy Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update

SAN DIEGO, March 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC ), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today reported financial results for the quarter and year ended December 31, 2014, and provided an update on its corporate activities and product pipeline. The company will host a webcast and conference call today at 4:30 p.m. ET.

Fourth Quarter 2014 and Subsequent Highlights

  • Submitted New Drug Application (NDA) to FDA for AuriPro TM : On February 25, 2015, Otonomy submitted an NDA to the U.S. Food and Drug Administration (FDA) for the approval of AuriPro as a treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement (TTP) surgery. The NDA submission is supported by data from two identical randomized, prospective, double-blind, sham-controlled Phase 3 clinical trials with a combined total of 532 pediatric patients. In both trials, AuriPro achieved the primary efficacy endpoint with statistical significance (p<0.001) and was well tolerated. If approved within the standard review period, Otonomy expects to launch the product in the United States during the first quarter of 2016.
     
  • Completed follow-on public offering: In January 2015, Otonomy completed a follow-on public offering of 2,932,500 shares of its common stock (including exercise of the underwriters' option to purchase an additional 382,500 shares) at an offering price of $29.25 per share. Proceeds from the follow-on offering were approximately $80 million, net of underwriting discounts, commissions and offering-related transaction costs.
     
  • Completed patient enrollment in Phase 2b trial of OTO-104 in Ménière's disease : In December 2014, Otonomy completed patient enrollment in its Phase 2b clinical trial of OTO-104 in patients with Ménière's disease. The prospective, randomized double-blind, placebo-controlled study is designed to assess the efficacy and safety of OTO-104 for the treatment of Ménière's disease, and to serve as one of two pivotal, single-dose efficacy trials required to support U.S. regulatory approval. The trial enrolled a total of 154 patients, exceeding the initial target of 140 patients. The company expects to report results from this trial during the second quarter of 2015 and, if results are positive, to initiate a second pivotal trial of OTO-104 in 2015. OTO-104 has been granted Fast Track designation by the FDA.
     
  • Obtained rights to clinical and non-clinical data for OTO-311 : In November 2014, Otonomy announced an exclusive licensing agreement with Ipsen under which Otonomy acquired rights to utilize Ipsen's clinical and non-clinical gacyclidine data in the development and registration of OTO-311, a sustained-exposure formulation of gacyclidine in development for the treatment of tinnitus.
     
  • Appointed experienced chief commercial officer: In October 2014, Otonomy appointed Anthony J. Yost as chief commercial officer. Mr. Yost brings 30 years of experience in pharmaceutical product sales and marketing that includes building and managing commercial teams at multiple companies.
     
  • Enrolled first patients in OTO-104 multiple-dose safety study : In October 2014, Otonomy enrolled the first patients in a multiple-dose safety study of OTO-104 in the United Kingdom in patients with Ménière's disease. The study is designed to evaluate the safety of quarterly dosing with OTO-104 and is expected to enroll 125 patients across multiple trial sites in the United Kingdom.

"Last year was a breakout year for Otonomy as we made significant progress on the clinical, corporate and financial fronts. We successfully completed Phase 3 trials for AuriPro, expanded our management team to support our transition to a commercial enterprise and secured significant funding with our successful IPO," said David A. Weber, Ph.D., chief executive officer and president of Otonomy. "I expect this year to be equally noteworthy given our recent follow-on offering and AuriPro NDA submission, as well as significant upcoming milestones including Phase 2b results for OTO-104 in Ménière's disease and planned initiation of clinical trials for both AuriPro and OTO-311."

Anticipated Upcoming Milestones

  • Results for the OTO-104 Phase 2b trial in Ménière's disease patients are expected during the second quarter of 2015.
     
  • Initiation of a clinical trial for AuriPro in one or more additional indications expected to begin in the first half of 2015.
     
  • Investigational New Drug (IND) filing and initiation of a Phase 1 clinical trial for OTO-311, a potential treatment for tinnitus, is expected in 2015.

Fourth Quarter and Full Year 2014 Financial Highlights

  • Cash, cash equivalents, and short-term investments totaled $156.0 million as of December 31, 2014, compared with $37.3 million as of December 31, 2013. In addition, Otonomy completed a follow-on public offering in January 2015 that provided proceeds of approximately $80 million net of underwriting discounts, commissions and offering-related transaction costs.
     
  • Operating expenses totaled $9.9 million for the fourth quarter of 2014 compared to operating expenses of $7.9 million for the fourth quarter of 2013. For the full year 2014, operating expenses totaled $39.6 million compared to $19.8 million for 2013.
     
  • Research and development expenses for the fourth quarter of 2014 were $7.2 million, compared with $6.6 million for the fourth quarter of 2013. The increase was primarily a result of additional clinical trial-related expenses for OTO-104. For the full year 2014, research and development expenses were $31.8 million compared to $16.3 million for 2013.
     
  • General and administrative expenses for the fourth quarter of 2014 were $2.7 million, compared to $1.2 million for the fourth quarter of 2013. The increase was primarily attributable to expanded operating activities, costs related to commercial preparation activities and costs associated with becoming a publicly traded company. For the full year 2014, general and administrative expenses were $7.8 million compared to $3.5 million for 2013.
     
  • Net loss for the fourth quarter of 2014 was $9.8 million, compared to net loss of $7.8 million for the fourth quarter of 2013. For the full year 2014, net loss was $42.9 million compared to $19.6 million for 2013.
     
  • Management expects operating expenses for 2015 to be in the range of $70-$75 million.

Conference Call and Webcast

Otonomy management will host a webcast and conference call regarding this announcement at 4:30 p.m. ET/1:30 p.m. PT today. The live call may be accessed by dialing (866) 953-6857 for domestic callers and (617) 399-3481 for international callers with conference code number: 61228517. A live webcast and archive of the call will be available from the investor relations section of the company website at www.otonomy.com . A telephone replay of the call will be available by dialing (888) 286-8010 for domestic callers or (617) 801-6888 for international callers and entering the conference code number: 90772974.

About Otonomy

Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic injection. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. A New Drug Application for AuriPro has been submitted to the FDA. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Ménière's disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information please visit www.otonomy.com .

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Otonomy's future financial or operating performance. Forward-looking statements in this press release include, but are not limited to, Otonomy's expectations regarding the commercial launch of AuriPro in the United States, the Phase 2b clinical trial of OTO-104 serving as one of two pivotal, single-dose efficacy trials required to support U.S. regulatory approval, the timing of results from the Phase 2b clinical trial of OTO-104, the initiation of a second pivotal trial of OTO-104, the expected enrollment for the multiple-dose safety study of OTO-104 in the United Kingdom, the initiation of a clinical trial for AuriPro in one or more additional indications, the timing of an IND filing with the FDA and initiation of a clinical trial for OTO-311, and estimated operating expenses for 2015. Otonomy's expectations regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties. Actual results may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: Otonomy's limited operating history and its expectation that it will incur significant losses for the foreseeable future; Otonomy's ability to obtain substantial additional financing; Otonomy's dependence on the regulatory and commercial success of AuriPro and OTO-104 and advancing additional product candidates, such as OTO-311; the uncertainties inherent in the clinical drug development process,including, without limitation, Otonomy's ability to adequately demonstrate the safety and efficacy of its product candidates, the preclinical and clinical results for its product candidates, which may not support further development of product candidates, and challenges related to patient enrollment in clinical trials; Otonomy's ability to obtain regulatory approval for its product candidates; side effects or adverse events associated with Otonomy's product candidates; competition in the biopharmaceutical industry; Otonomy's dependence on third parties to conduct preclinical studies and clinical trials; Otonomy's dependence on third parties for the manufacture of products; Otonomy's dependence on a small number of suppliers for raw materials; Otonomy's ability to protect its intellectual property related to product candidates in the United States and throughout the world; expectations regarding potential market size, opportunity and growth; Otonomy's ability to manage operating expenses; implementation of Otonomy's business model and strategic plans for its business, products and technology;; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in Otonomy's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 18, 2015, and Otonomy's future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Otonomy as of the date hereof. Otonomy disclaims any obligation to update any forward-looking statements, except as required by law.

Otonomy, Inc.
Condensed Balance Sheet Data
(in thousands)
     
  As of December 31,
  2014 2013
     
Cash and cash equivalents  $ 139,810  $ 37,284
     
Short-term investments  16,223  -- 
     
Total assets  159,164  39,757
     
Total liabilities  5,551  3,581
     
Accumulated deficit  (102,469)  (59,557)
     
Total stockholders' equity (deficit)   153,613  (58,977)
     
     
Otonomy, Inc.
Condensed Statements of Operations
(in thousands, except share and per share data)
         
  Three Months Ended Years Ended
  December 31, December 31,
  2014 2013 2014 2013
  (unaudited)    
Operating expenses:        
Research and development  $ 7,187  $ 6,638  $ 31,803  $ 16,336
General and administrative  2,667  1,230  7,836  3,514
Total operating expenses  9,854  7,868  39,639  19,850
Loss from operations  (9,854)  (7,868)  (39,639)  (19,850)
         
Other income (expense)  60  111  (3,238)  291
Net loss  (9,794)  (7,757)  (42,877)  (19,559)
Accretion to redemption value of convertible preferred stock  --  (13)  (35)  (539)
Net loss attributable to common stockholders  $ (9,794)  $ (7,770)  $ (42,912)  $ (20,098)
         
Net loss per share attributable to common stockholders, basic and diluted  $ (0.46)  $ (103.15)  $ (5.46)  $ (268.79)
         
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted  21,158,394  75,325  7,853,228  74,772
         

Media Inquiries Canale Communications Heidi Chokeir, Ph.D. Vice President 619.849.5377 Investor Inquiries Westwicke Partners Robert H. Uhl Managing Director 858.356.5932

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 60

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 479

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading

Top 5 Most Recently Viewed Articles

Day One Biopharmaceuticals Set to Announce Q4 Earnings Soon

Updated Category News Views 100

Day One Biopharmaceuticals Announces Financial Results Call Day One Biopharmaceuticals (NASDAQ: DAWN) is making new strides in the biopharmaceutical sector, focusing on therapies that target significant health challenges affecting individuals of all ages. The company has scheduled a live conference call for stakeholders, during which they will release their financial...

Continue Reading
Celebrating Daniel P. O'Toole's Prestigious Legal Achievement

Updated Category News Views 208

Daniel P. O'Toole Celebrated as 'Lawyer of the Year' Daniel P. O'Toole, managing partner of the renowned Block O'Toole & Murphy, has been bestowed with the prestigious 2026 'Lawyer of the Year' honor in Personal Injury Litigation – Plaintiff by Best Lawyers. This recognition, awarded only to one attorney per year in each specialty and area, underscores the remarkable...

Continue Reading
Jeffrey Pribor Sells Options for $535K, Insights from INSW

Updated Category News Views 180

Key Insider Activity in International Seaways Recently, a significant stock option exercise by Jeffrey Pribor, who serves as SVP & CFO at International Seaways (NYSE: INSW), was made public through a recent SEC filing. This exercise is a notable insider transaction, which can provide insights into the company’s financial activities. What Transpired with the Stock...

Continue Reading
Join Elkem ASA in Shaping a Sustainable Future Today

Updated Category News Views 221

Elkem ASA Annual General Meeting in 2025 Elkem ASA is hosting its annual general meeting on 30 April 2025. This gathering will take place online at 09:30 (CEST) via the Lumi AGM platform, providing a convenient digital experience for all shareholders. The meeting will include a live webcast and feature electronic voting, allowing participants to engage seamlessly from any...

Continue Reading
Industrial Safety Gates Market Growth Driven by Innovative Features

Updated Category News Views 175

Industrial Safety Gates Market Growth Driven by Innovative Features The industrial safety gates market is on the rise, with projections estimating growth of USD 140.9 million from 2024 to 2028. This increase is propelled by key features such as self-closing mechanisms and ongoing advancements in artificial intelligence (AI). Companies operating within this market are...

Continue Reading